C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR.

Slides:



Advertisements
Similar presentations
Removal of Prions by Plasma Fractionation Processes
Advertisements

Experience of the Irish Blood Transfusion Service William G. Murphy MD
® Bovine Derived Products are Safe TSE Advisory Committee Serologicals Corporation February 2004.
Draft Guidance for Industry: Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob.
Leucocyte depleted blood products. BCSH;Transfusion Medicine, 1998,8,59-71 Dr. Tariq Roshan 23 rd March 2003.
Tomo Yokomizo, Morikazu Miura
Dynamic Light Scattering Measuring Platelet Quality and Bacterial Contamination Elisabeth Maurer, Ph.D. Canadian Blood Services, R&D Vancouver UBC, Department.
Platelet Refractoriness
Single-Donor Platelets: Arguments for Preferential Use Paul M. Ness, MD Transfusion Medicine Division Johns Hopkins Medical Institutions.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Presumptive Transfusion Transmissions of vCJD: Introduction to Consideration of Current FDA-recommended Safeguards FDA TSE Advisory Committee 16 th Meeting.
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Preclinical – Animal Study
CELL MEMBRANE MICROPARTICLES IN BLOOD AND BLOOD PRODUCTS: POTENTIALLY PATHOGENIC AGENTS AND BIOMARKERS JAN SIMAK, Ph.D. Laboratory of Cellular Hematology,
THE RATIONAL USE OF BLOOD AND BLOOD PRODUCTS
Good Manufacturing Practices for Blood Establishments
Transmissible Spongiform Encephalopathies Advisory Committee 23 rd Meeting Gaithersburg, MD – August 1, 2011 CJD and vCJD Donor Policies: Blood and Blood.
Transfusion of Blood Product History: 1920:Sodium citrate anticoagulant(10 days storage) 1958: Plastic bag of transfusion 1656: Initial theory and.
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
Supercourse Environmental Exposure Assessment And Biomarkers Wael Al-Delaimy, MD, PhD.
Food and Drug Administration Food and Drug Administration Center for Biologics Evaluation and Research Biological Response Modifiers Advisory Committee.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Evaluation of Viral Clearance Studies
TSE Advisory Committee October 14, 2004, Silver Spring, MD Removal of blood-borne TSE infectivity by leukoreduction filters Luisa Gregori V.A. Medical.
MEDICAL TESTING Doctor requires information Patient sample collection
Blood Component Therapy
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Apheresis Blood Components
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
Complete Blood Count.
Leukocyte-Reduced Blood Components Lore Fields MT(ASCP)SBB Consumer Safety Officer, DBA, OBRR, CBER September 16, 2009.
Workshop on Leukocyte Reduction of Blood and Blood Components: An Update Alan E. Williams, Ph.D. Division of Blood Applications OBRR/CBER/FDA July 20,
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
Proposed algorithm for approval of human TSE tests in Europe.
Removal of Infectious Prions from Red Cell Concentrates Samuel Coker, PhD Principal Scientist and Technical Director Pall Medical Transmissible Spongiform.
Current CBER Safeguards for Blood Products: Approach to Products Containing or Exposed to Bovine Materials TSE Advisory Committee February 13, 2004 Dorothy.
12 August 2003 CJD Update Latest facts, figures & findings Jonathan P Clewley TSE Unit, Virus Reference Division, Centre for Infections 20 May 2005.
Laboratory of Cellular Hematology
FDA’s Criteria for Evaluation of Red Blood Cell Products Ping He, M.D. Medical Officer Blood Products Advisory Committee 91st Meeting, May 1, 2008 Rockville.
FDA Update: Particulate Matter Task Force Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting June 19, 2003.
TSE Clearance Studies for pdFVIII: Study Methods and Clearance Levels TSE Advisory Committee September 18, 2006 Dorothy Scott, M.D. Office of Blood Research.
19 September 2006 Gaithersburg, MD David Peretz M.Sc., D.Sc. Senior Scientist CHIRON Submission To FDA TSE Advisory Committee Meeting.
1 Nonprescription Drugs AC Meeting March 23, 2005 Efficacy of OTC Healthcare Antiseptics: Introduction to the Regulatory Issues Susan S. Johnson, Pharm.D.,
18 th Meeting of FDA TSE Advisory Committee: 31 October 2005 Summary FDA Blood Products Advisory Committee 85 th Meeting 03 November 2005 Holiday Inn Gaithersburg.
Prion cell tropism significantly varies among animal species, depending on both the agent strain and host-specific factors. For example, prions show high.
TSE Agent Clearance Issues TSE Advisory Committee February 20, 2003 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
Founders With the support of. 2 Letters of intent  Individual quotation, then selection by the SAB Validation by the Bureau  Full Application  Individual.
Preparation of blood components
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
Draft Risk Assessment for UK manufactured Factor XI and Potential vCJD Exposure Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center.
Evaluation of Viral Clearance Studies Mahmood Farshid, Ph.D. Div. Of Hematology OBRR/ CBER/FDA.
Review of Publicly Available Information on TSE Clearance by Steps Used to Manufacture FVIII Products TSE Advisory Committee October 31, 2005 Dorothy Scott,
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
Jaro Vostal, MD, PhD Division of Hematology, OBRR, CBER, FDA
TSE Task Force Prion reduction evaluation in the manufacturing of plasma protein therapies Dr. Henry Baron, Chair, PPTA TSE Task Force.
Preliminary Risk Assessment Model for U.S. Plasma Derivatives and vCJD Steven Anderson, PhD, MPP Office of Biostatistics & Epidemiology Center for Biologics.
Risk Assessment: Questions to the Committee 1.What estimate(s) should be used to reflect the prevalence of vCJD in the U.K.? Proposal: We propose using.
Topic 1: FDA Draft Guidance “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and vCJD by Blood and Blood Products” Dorothy.
David M. Asher, MD Division of Emerging & Transfusion-Transmitted Diseases Office of Blood Research & Review Center for Biologics Evaluation & Research.
Statistical Methods in the Evaluation of Red Blood Cell Products (In vivo study) Jessica Kim, Ph.D. Mathematical Statistician FDA/CBER/OBE/DB Blood Products.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
TOPIC II Potential Screening Assays to Detect Blood and Plasma Donors Infected with TSE Agents: Possible Criteria for Validation Pedro Piccardo, MD LBPUA,
Transfusion Related Acute Lung Injury (TRALI)
Proposed Animal Study to Evaluate Simian Foamy Virus (SFV) Transmission by Blood Arifa S. Khan, Ph.D. DVP, OVRR, CBER, FDA BPAC, December 13, 2001.
Blood Preservation and Storage
Consideration of reducing the shelf life of SAGM RBCs
EXTENT OF CHANGES IN PRE AND POSTDONATION DONOR VARIABLES IN SINGLE AND DOUBLE DOSE PLATELETPHERESIS AND ITS IMPLICATIONS ON DONOR SAFETY Dr. R. Sreedevi.
Presentation transcript:

C B E R E R Vostal 10/2005 Labeling Claims for TSE Reduction Studies with Blood Processing Filters Jaro Vostal, M.D., Ph.D. Division of Hematology, OBRR

C B E R E R Vostal 10/2005 Normal prion protein (PrPc) Conversion of PrPc to PrPsc Pathologic prion protein (PrPsc) Protease resistant less soluble Accumulated PrPsc and neurotoxicity Altered conformations of PrPc TSE infectivity present

C B E R E R Vostal 10/2005 spleen stomach CNS neuron CNS Transport of TSE from peripheral inoculum to the CNS

C B E R E R Vostal 10/2005 Asymptomatic BSE infected sheep Healthy sheep BSE infected sheep Blood transfusion BSE transmission by blood transfusion Houston, F. et al. Lancet 2000 Hunter, N. et al. J. Gen Virology, 2002 X X

C B E R E R Vostal 10/2005 Epidemiological evidence for vCJD transmission by blood transfusion in humans Llewelyn, C.A. et al, Lancet 363: , 2004 Peden, A.H. et al. Lancet 364: , 2004 The UK National CJD surveillance system identified individuals (48 total, 17 alive) who received blood products from 15 donors who later became diagnosed as vCJD cases 2 living recipients were subsequently diagnosed with vCJD –1 developed and died from symptoms of vCJD –1 died for unrelated cause and was unsymptomatic for vCJD but had PrPres identified in spleen Both received non-leukoreduced red cells

C B E R E R Vostal 10/2005 Issues to consider for validation of devices and processes used to reduce TSE infectivity in human blood Distribution of TSE infectivity in blood Cell-associated –Intracellular vs extracellular Free floating in plasma –Physical attributes of infectivity (aggregates, fibrils, microvesicles) Interaction of the individual units of infectivity with the devices Distribution during and after processing –(microparticle generation)

C B E R E R Vostal 10/2005 Steps to validate TSE reduction efficacy claims In vitro spiking studies of TSE infectivity into human blood –Detection of infectivity by surrogate markers (PrPres) or by bioassay Endogenous TSE infectivity in an animal model –Detection of infectivity by bioassay

C B E R E R Vostal 10/2005 Predictive value of animal models for human situation Comparability of animal blood to human blood –Cell type number, size and physical properties of blood cells –Interaction of animal and human blood cells with different materials Transmissibility or infectivity of a TSE agent may be influenced by –Strain of agent used –The dose of agent –Distribution of infectivity in blood –Distribution of normal prion ?

C B E R E R Vostal 10/2005 Hematologic values for various species SpeciesRBC count x 10 6 / uL RBC MCV (fL) WBC Count x 10 3 / uL Platelet x 10 3 / uL Sheep Golden Hamster Mouse Human Schalm, O.W. Veterinary Hematology, 2 nd ed. Lea & Febiger, Philadelphia 1965 Harrison, Principles of Internal Medicine, 17 th ed. McGraw-Hill, 1994

C B E R E R Vostal 10/2005 PrPc expression on blood cells of different species Vostal, J.G. and Holada, K. Transf Med Rev. 15: , 2001

C B E R E R Vostal 10/2005 Validation of TSE infectivity reduction is only one part of the evaluation process TSE reduction devices also need to be evaluated for their impact on transfusion product quality Evaluation of red cells, platelets or plasma FDA follows a standardized evaluation approach to each transfusion product based on previous experience with devices that process transfusion products (e.g. leukoreduction filters)

C B E R E R Vostal 10/2005 Leukoreduction: the process of reducing the total number of leukocytes in a transfusion component Methods:filtration of blood products or collection of products by apheresis Use of leukoreduced blood products has been associated with reduction of –febrile non hemolytic transfusion reactions –Alloimmunization –Cytomegalovirus (CMV) No claims by manufacturers for their devices beyond meeting the criteria for leukoreduction –US <5x10 6 leukocytes per transfusion product –Europe <1x10 6 leukocytes per transfusion product

C B E R E R Vostal 10/2005 Validation of Leukoreduction Filters-Efficacy Quantitation of leukocytes in particular blood product before and after filtration –Whole blood, red cells, platelets, plasma Define timing of leukoreduction from time of collection Explore effects of temperature on filtration efficacy (room vs cold temperatures) Validation specific for particular anticoagulant

C B E R E R Vostal 10/2005 Validation of Leukoreduction Filters-Safety Biocompatibility and integrity of materials Effect on cellular products –In vitro recovery (85%) –Hemolysis at end of storage (<1%) –In vivo recovery of radiolabelled cells (platelets and red cells) Plasma – –Levels and function of plasma proteins –Complement activation

C B E R E R Vostal 10/2005 FDA proposal for validating a claim of reducing TSE infectivity in human blood products Demonstrate reduction of endogenous TSE infectivity by bioassay in two animal models (rodent and sheep) Use full scale blood unit and leukoreduction filter TSE infectivity from BSE or vCJD strain Reduction of PrPsc in blood product will be considered supportive but not sufficient for a claim Study performed at two separate sites to minimize issues of cross contamination and differences in laboratory practice Study size sufficient to support statistically valid conclusion

C B E R E R Vostal 10/2005 Question 1:Are the FDA’s proposed minimal criteria for validation of TSE infectivity reduction by filtration adequate and appropriate? Please comment on the following points A) Rationale for the use of specific animal models to study the properties of blood-borne TSE infectivity (Are experiments in rodents sufficient, or should experiments also be done in sheep?) B) Is it necessary that each experiment should be done at two separate laboratory sites (i.e. to ensure reproducibility, and accuracy of clearance)? C) General description of informative scaled-down processes for reducing TSE infectivity in blood

C B E R E R Vostal 10/2005 Question 1:Are the FDA’s proposed minimal criteria for validation of TSE infectivity reduction by filtration adequate and appropriate? Please comment on the following points D) Levels of clearance acceptable for claims of reduced TSE infectivity in blood components as used in clinical settings E) Estimated logs of clearance of TSE infectivity required to conclude that blood filters have effectively removed infectivity from blood components F) Methodology appropriate to use in evaluating TSE agent clearance (bioassays for infectivity, Western blot or other assay for prion proteins, other methods)

C B E R E R Vostal 10/2005 Question 2: Does the FDA’s proposed labeling for a filter meet the appropriate criteria for a claim of reduction of TSE infectivity in blood or blood components? A) This filter (device) has been shown to reduce TSE infectivity in blood from an infected animal model. or B) This filter (device) has been shown to reduce transmission of TSE infectivity by transfusion in an animal model. and (A+C or B+C) C) Due to lack of feasibility, studies have not been performed to validate this claim in a human population.